Efficacy in Daily Use of a Novel Skin Care Product for the Treatment of Photoaged Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-01

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Photoaged or chronically sun-exposed skin is characterised by a number of clinical features including fine and coarse wrinkles. The pathogenesis of wrinkle formation has yet to be determined fully but recent work suggests that ultraviolet radiation-induced reduction in dermal fibrillin (in the form of fibrillin-rich microfibrils) is important. Using an extended in vivo patch test assay, it has been identified that skin care products - currently marketed by CG Skin Ltd - increase the deposition of these microfibrils in photoaged dermis and hence have the potential to repair photoaged skin. The Investigators now propose to examine the efficacy of the product in randomized, placebo-controlled clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate and Compare the Efficacy of Two Facial Creams on Moderately to Severely Photodamaged Skin

NCT06852742

Photodamaged Skin

COMPLETED NA

Efficacy and Tolerance Evaluation of a "Revitalizing" Face Treatment

NCT03276897

Face Aging/Photo Aging of Moderate Grade

COMPLETED NA

Efficacy of Four Topical Products to Improve Skin Longevity

NCT07118943

Aging Wrinkle

COMPLETED NA

Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage

NCT02422836

Skin Manifestations

COMPLETED NA

A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+

NCT06148558

Anti-aging Photoaging

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects who satisfy the inclusion/exclusion criteria and who have given their written, witnessed, informed consent will be admitted to the studies. Subjects will be clinically assessed (fine wrinkling, coarse wrinkling, mottled hyperpigmentation, sallowness) and clinical photographs taken prior to instruction on the use of the allocated cream by the study Investigator (product or placebo). Product will be applied daily to the entire face and dorsum of hands, including the wrists and extensor forearm, for six months. Successive follow-up visits (3 visits over a 6-month period) will be made to assess efficacy and safety. Subjects will be randomly allocated to self-treatment with either product or placebo cream using a computer generated code (Research Randomizer; www.randomizer.org).

The primary outcome measure will be treatment efficacy; this will be assessed by the study Investigators as changes in the clinical parameters of photoaging (fine wrinkles, coarse wrinkles, mottled hyperpigmentation, sallowness).

The Investigators will assess two secondary outcome measures: (1) Histological improvement in skin structure. Skin biopsies from the treated extensor forearm will be taken at study initiation and at the end of the six month study period. These biopsies will be evaluated for: (a) epidermal thickness; (b) fibrillin expression and; (c) pro-collagen I expression. (2) Tolerance and irritancy. Tolerance and irritation assessments will be made by recording the occurrence and severity of signs of erythema and scaling. Safety will be evaluated by recording all adverse events experienced by subjects. Any subject exhibiting adverse events of sufficient severity will be withdrawn from the trial. Completion or withdrawal of subjects from the trial will be noted on the end of study form. All subjects will be monitored for the occurrence of serious adverse events up to, and including, 28 days after their involvement with this study.

The trial will be conducted according to the recommendations of ICH GCP and those of the Declaration of Helsinki, only after approval of the study has been obtained from the relevant Research Ethics Committee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Photoaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Assessment of efficacy of a novel anti-aging topical treatment compared to a placebo control

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Topical anti-aging cosmetic cream (active)

Group Type EXPERIMENTAL

Topical anti-aging cosmetic cream

Intervention Type OTHER

Topical anti-aging cosmetic cream

Placebo

Basic formulation without active ingredients (vehicle)

Group Type PLACEBO_COMPARATOR

Topical anti-aging cosmetic cream

Intervention Type OTHER

Topical anti-aging cosmetic cream

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical anti-aging cosmetic cream

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have moderate to severe photoaging of facial skin (grade 6 or above on the Griffiths scale);
* Willing to submit to examination of facial skin, hands and forearms;
* Willing to submit to self-treatment with product or placebo cream on face, hands and forearms, including wrists and extensor forearms, for 6 months;
* Willing to submit to clinical photography;
* Willing to submit to 3 mm punch biopsies from the wrist at beginning and end of trial;
* Signed informed consent.

Exclusion Criteria

* Skin disease that would impair evaluation of the test sites;
* Topical or systemic retinoid within the past 6 months and 12 months respectively prior to entry to the study;
* Topical steroid or other topical drugs at treatment sites for at least two weeks prior to study entry;
* History of use of experimental drug or experimental device in the 30 days prior to entry into the study;
* Any significant cosmetic treatment for skin rejuvenation i.e. dermabrasion, chemical peels, face-lifts;
* Known allergy to any of the product or placebo ingredients;
* History of keloid scars.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes